Debate: Should the dose or duration of anticoagulants for the prevention of venous thrombosis be increased in patients with COVID-19 while we are awaiting the results of clinical trials?
作者信息
Gomez Keith, Laffan Mike, Bradbury Charlotte
机构信息
Haemophilia Centre and Thrombosis Unit, Royal Free Hospital London NHS Foundation Trust, London, UK.
Department of Immunity and Inflammation, Centre for Haematology, Faculty of Medicine, Imperial College London, London, UK.
出版信息
Br J Haematol. 2021 Feb;192(3):459-466. doi: 10.1111/bjh.17241. Epub 2020 Nov 25.
Abstract
摘要
相似文献
1
Debate: Should the dose or duration of anticoagulants for the prevention of venous thrombosis be increased in patients with COVID-19 while we are awaiting the results of clinical trials?辩论：在等待临床试验结果期间，新冠病毒病患者预防静脉血栓形成的抗凝剂剂量或疗程是否应增加？
Br J Haematol. 2021 Feb;192(3):459-466. doi: 10.1111/bjh.17241. Epub 2020 Nov 25.
2
Anticoagulation for COVID-19 Patients: A Bird's-Eye View.COVID-19 患者的抗凝治疗：鸟瞰。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039288. doi: 10.1177/10760296211039288.
3
Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era.急性病医学患者静脉血栓栓塞症的预防：新时代。
Semin Respir Crit Care Med. 2021 Apr;42(2):308-315. doi: 10.1055/s-0041-1723018. Epub 2021 Feb 6.
4
Cerebral venous thrombosis post BNT162b2 mRNA SARS-CoV-2 vaccination: A black swan event.BNT162b2 mRNA新冠疫苗接种后发生脑静脉血栓形成：一个黑天鹅事件。
Am J Hematol. 2021 Sep 1;96(9):E357-E361. doi: 10.1002/ajh.26272. Epub 2021 Jun 26.
5
Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?COVID-19 患者的血栓预防存在种族差异：是否应该考虑这些差异？
Int J Hematol. 2021 Mar;113(3):330-336. doi: 10.1007/s12185-021-03078-x. Epub 2021 Jan 20.
6
COVID-19 and thrombosis: Prophylaxis and management.2019冠状病毒病与血栓形成：预防与管理
Tuberk Toraks. 2021 Jun;69(2):269-278. doi: 10.5578/tt.20219818.
7
Deep vein thrombosis in hospitalized patients with coronavirus disease 2019.COVID-19 住院患者的深静脉血栓形成。
J Vasc Surg Venous Lymphat Disord. 2021 May;9(3):597-604. doi: 10.1016/j.jvsv.2020.09.010. Epub 2020 Oct 8.
8
Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients: Venous thrombosis prevention & COVID-19.增加抗凝治疗可降低机械通气的新冠肺炎患者近端深静脉血栓形成风险：静脉血栓预防与新冠肺炎
J Infect. 2021 May;82(5):186-230. doi: 10.1016/j.jinf.2020.11.019. Epub 2020 Nov 20.
9
Deep vein thrombosis in noncritically ill patients with coronavirus disease 2019 pneumonia: deep vein thrombosis in nonintensive care unit patients.COVID-19 肺炎非危重症患者的深静脉血栓形成：非重症监护病房患者的深静脉血栓形成。
J Vasc Surg Venous Lymphat Disord. 2021 May;9(3):592-596. doi: 10.1016/j.jvsv.2020.08.028. Epub 2020 Sep 7.
10
COVID-19 as a novel etiology of portal vein thrombosis: change in the current management concepts.新型冠状病毒肺炎作为门静脉血栓形成的新病因：当前管理理念的转变
Infect Dis (Lond). 2021 Feb;53(2):148-150. doi: 10.1080/23744235.2020.1837943. Epub 2020 Oct 22.
引用本文的文献
1
Coagulation biomarkers and coronavirus disease 2019 phenotyping: a prospective cohort study.凝血生物标志物与2019冠状病毒病表型分析：一项前瞻性队列研究。
Thromb J. 2023 Jul 28;21(1):80. doi: 10.1186/s12959-023-00524-0.
2
High-Dose Prophylactic Anticoagulation for COVID-19 Pneumonia: A Review of Benefits and Risks.COVID-19肺炎的高剂量预防性抗凝治疗：益处与风险综述
Cureus. 2023 Apr 17;15(4):e37705. doi: 10.7759/cureus.37705. eCollection 2023 Apr.
3
Retroperitoneal and abdominal bleeding in anticoagulated COVID-19 hospitalized patients: Case series and brief literature review.抗凝治疗的新冠肺炎住院患者的腹膜后及腹部出血：病例系列及文献综述
World J Clin Cases. 2023 Mar 6;11(7):1528-1548. doi: 10.12998/wjcc.v11.i7.1528.
4
The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury.肥胖与新冠后遗症：低氧血症、血栓性炎症和血管内皮损伤。
Front Cardiovasc Med. 2023 Feb 7;10:1062491. doi: 10.3389/fcvm.2023.1062491. eCollection 2023.
5
Reply to Bareille et al. Are Viscoelastometric Assays of Old Generation Ready for Disposal? Comment on "Volod et al. Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices. 2022, , 860".回复巴雷耶等人。旧一代粘弹性检测方法是否已准备好被淘汰？评“沃洛德等人。粘弹性止血检测：传统与新一代设备入门。2022年，，860”。
J Clin Med. 2023 Jan 6;12(2):478. doi: 10.3390/jcm12020478.
6
Effect of intermediate/high versus low dose heparin on the thromboembolic and hemorrhagic risk of unvaccinated COVID-19 patients in the emergency department.未接种疫苗的 COVID-19 患者在急诊科中使用中/高剂量肝素与低剂量肝素对血栓栓塞和出血风险的影响。
BMC Emerg Med. 2022 Jun 14;22(1):107. doi: 10.1186/s12873-022-00668-8.
7
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.抗血小板治疗对COVID-19重症患者生存及无器官支持天数的影响：一项随机临床试验
JAMA. 2022 Apr 5;327(13):1247-1259. doi: 10.1001/jama.2022.2910.
8
Anticoagulation in COVID-19.新冠疫情中的抗凝治疗
Lancet. 2022 Jan 1;399(10319):5-7. doi: 10.1016/S0140-6736(21)02503-4. Epub 2021 Dec 15.
9
Spontaneous retroperitoneal hematoma: a rare bleeding occurrence in COVID-19.自发性腹膜后血肿：COVID-19中一种罕见的出血情况。
Oxf Med Case Reports. 2021 Sep 13;2021(9):omab081. doi: 10.1093/omcr/omab081. eCollection 2021 Sep.
10
Preventing Thrombohemorrhagic Complications of Heparinized COVID-19 Patients Using Adjunctive Thromboelastography: A Retrospective Study.使用辅助血栓弹力图预防肝素化新冠肺炎患者的血栓出血并发症：一项回顾性研究
J Clin Med. 2021 Jul 14;10(14):3097. doi: 10.3390/jcm10143097.
本文引用的文献
1
Efficacy and Safety of D-dimer, Weight, and Renal Function-Adjusted Thromboprophylaxis in Patients with Coronavirus Disease 2019 (COVID-19).D-二聚体、体重及肾功能调整的血栓预防措施在2019冠状病毒病（COVID-19）患者中的疗效与安全性
Semin Thromb Hemost. 2021 Jun;47(4):436-441. doi: 10.1055/s-0040-1722309. Epub 2021 Jan 22.
2
Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia.新冠病毒肺炎住院患者的抗凝强度与生存率
Thromb Res. 2020 Dec;196:375-378. doi: 10.1016/j.thromres.2020.09.030. Epub 2020 Sep 23.
3
Development and implementation of a COVID-19 near real-time traffic light system in an acute hospital setting.在急性医院环境中开发和实施 COVID-19 近实时信号灯系统。
Emerg Med J. 2020 Oct;37(10):630-636. doi: 10.1136/emermed-2020-210199. Epub 2020 Sep 18.
4
Thrombotic and haemorrhagic complications in critically ill patients with COVID-19: a multicentre observational study.COVID-19 重症患者的血栓和出血并发症：一项多中心观察研究。
Crit Care. 2020 Sep 18;24(1):561. doi: 10.1186/s13054-020-03260-3.
5
Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration.COVID-19 住院患者的抗凝干预措施：随机对照试验的范围综述及国际合作呼吁。
J Thromb Haemost. 2020 Nov;18(11):2958-2967. doi: 10.1111/jth.15094. Epub 2020 Oct 1.
6
Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19.COVID-19 住院患者的抗凝、出血、死亡率和病理学。
J Am Coll Cardiol. 2020 Oct 20;76(16):1815-1826. doi: 10.1016/j.jacc.2020.08.041. Epub 2020 Aug 26.
7
Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19.COVID-19 住院患者 D-二聚体升高的患病率和结局。
Arterioscler Thromb Vasc Biol. 2020 Oct;40(10):2539-2547. doi: 10.1161/ATVBAHA.120.314872. Epub 2020 Aug 25.
8
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.新型冠状病毒肺炎肺血管内凝血病变的免疫机制
Lancet Rheumatol. 2020 Jul;2(7):e437-e445. doi: 10.1016/S2665-9913(20)30121-1. Epub 2020 May 7.
9
Postdischarge thrombosis and hemorrhage in patients with COVID-19.COVID-19 患者出院后的血栓形成和出血。
Blood. 2020 Sep 10;136(11):1342-1346. doi: 10.1182/blood.2020007938.
10
Postdischarge venous thromboembolism following hospital admission with COVID-19.COVID-19 住院后出院后的静脉血栓栓塞症。
Blood. 2020 Sep 10;136(11):1347-1350. doi: 10.1182/blood.2020008086.
Zotero 插件